| Category | BioTech |
| Phone | 949-477-8090 |
| Employees | |
| Founded | 2001 |
| TOTAL | $4.92M |
| FUNDING TOTAL | $4.92M |
| Venture Round, 8/05 SCO Capital Partners | $1.25M |
| Venture Round, 1/06 Whalehaven Capital Fund SCO Capital Partners Alpha Capital BF Holding Xmark Asset Management | $3.67M |
Somanta Pharmaceuticals a development stage biopharmaceutical company, develops drugs primarily for the treatment of cancer. It holds a license to develop Sodium Phenylbutyrate for the treatment of cancer, autoimmune diseases, and other clinical indications. The company’s products in the pre-clinical stage of development include Alchemix, which is intended to interrupt various phases of the cancer cell growth cycle by selectively binding to DNA and inhibiting DNA processing enzymes to overcome drug resistant tumors.
